AstraZeneca will present 84 abstracts, including 12 oral presentations and three late-breaking abstracts, across its industry-leading renal portfolio which includes roxadustat, Farxiga (dapagliflozin) and Lokelma (sodium zirconium cyclosilicate), at ASN Kidney Week 2020 Reimagined, taking place virtually from 22-25 October 2020.

The data advance AstraZeneca’s ambition to create a coordinated pathway for renal patients to advance earlier diagnosis and help prevent or slow the progression of chronic kidney disease (CKD) and address its life-threatening complications, such as anaemia and hyperkalaemia.

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: “The breadth of data being presented by AstraZeneca demonstrates the growing momentum of our renal portfolio. Our ambition is to provide new treatments for hundreds of millions of patients with chronic kidney disease, a progressive condition for which there currently is no cure. We are particularly excited to share insights into the safety and efficacy of roxadustat in anaemia of chronic kidney disease and new subgroup data from the DAPA-CKD trial looking at the benefit of Farxiga regardless of disease cause.”